The International Association for the Study of Lung Cancer (IASLC) education teams will travel to various geographical locations within their regions in order to teach others the importance of and how to implement molecular testing using small group interactive learning sessions and hands-on approaches. The educational team will consist of medical oncologists, surgeons, pulmonologists, interventional radiologists, pathologists, nurses, laboratory personnel, molecular biologists, cytogeneticists, bioinformaticists and other scientists.
Oncoceutics Inc. and the University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug.
New levels of collaboration between researchers in food science, pharmacy and chemistry have been pioneered at the University of Huddersfield. The three-man team of scientists behind the development have launched a conference that is set to become a regular event around the UK, and have co-edited a special edition of the key academic journal in their field called Food Hydrocolloids.
Aarhus University recently received USA patent protection for a new method holding promise for various applications ranging from predicting risk and early diagnosis of disease to design of personalized treatments for patients.
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the launch of a new virtual journal: Atlas. Published as a virtual journal, Atlas selects already published research on topics that hold high societal relevance or address global issues, and summarizes and presents the science in a lay-friendly, story format to reach an as wide as possible global audience.
The J-NDA is supported by a pivotal Phase 2 trial showing that in Japanese patients Yondelis (trabectedin) provided clinical benefit, resulting in a significantly superior median progression-free survival compared to best supportive care (5.6 versus 0.9 months). The NDA will receive priority review by regulatory agency and will seek approval for various subtypes of advanced soft-tissue sarcoma in Japan.